Journal of the Neurological Sciences
Volume 283, Issue 1 , Pages 219-223 , 15 August 2009

Nicardipine use in cerebrovascular disease: A review of controlled clinical studies

  • Francesco Amenta

      Affiliations

    • Clinical Research Centre, Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Italy
    • Corresponding Author InformationCorresponding author. Centro Ricerche Cliniche, Dipartimento Medicina Sperimentale e Sanità Pubblica Via Madonna delle Carceri, 962032 Camerino, Italy. Tel./fax: +39 0737 403311.
    • ,
  • Alessia Lanari

      Affiliations

    • Stroke Unit, Division of Neurology, “Carlo Poma” Hospital, 46100 Mantova, Italy
    • ,
  • Fiorenzo Mignini

      Affiliations

    • Clinical Research Centre, Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Italy
    • ,
  • Giorgio Silvestrelli

      Affiliations

    • Stroke Unit, Division of Neurology, “Carlo Poma” Hospital, 46100 Mantova, Italy
    • ,
  • Enea Traini

      Affiliations

    • Clinical Research Centre, Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Italy
    • ,
  • Daniele Tomassoni

      Affiliations

    • Clinical Research Centre, Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Italy

References 

  1. Liebson PR. Calcium channel blockers in the spectrum of antihypertensive agents. Expert Opin Pharmacother. 2006;7:2385–2401
  2. Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med. 2004;116:35–43
  3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751–1762
  4. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591–603
  5. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs. 2007;67:1309–1327
  6. Rinkel GJE, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurismal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2005;1:CD000277
  7. Sabbatini M, Strocchi P, Amenta F. Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders. Clin Exp Hypertens. 1995;17:719–750
  8. Liu-Deryke X, Rhoney DH. Cerebral vasospasm after aneurismal subarachnoid haemorrhage: an overview of pharmacologic management. Pharmacotherapy. 2006;26:182–203
  9. Stippler M, Crago E, Levy EI, Kerr ME, Yonas H, Horowitz MB, et al. Magnesium infusion for vasospasm prophylaxis after subarachnoid haemorrhage. Neurosurg. 2006;105:723–729
  10. Flamm ES, Adams HP, Beck DW, Pinto RS, Marler JR, Walker MD, et al. Dose-escalation study of intravenous nicardipine in patients with aneurismal subarachnoid haemorrhage. J Nerosurg. 1988;68:393–400
  11. Montarry M, Chacornac R, Philippon B, Bouchet CI, Guichard P. Effects of an intravenous injection of nicardipine on cerebral blood flow in subarachnoid haemorrhage caused by intracranial aneurysm. Agressologie. 1989;30:411–415
  12. Combes P, Fauvage B. Systemic vasomotor interaction between nicardipine and hypocapnic alkalosis in man. Intensive Care Med. 1992;18:89–92
  13. Beck DW, Adams HP, Flamm ES, Godersky JC, Loftus CM. Combination of aminocaproic acid and nicardipine in treatment of aneurismal subarachnoid haemorrhage. Stroke. 1988;19:63–67
  14. Fujita K, Yamashita H, Masamura M, Ehara K, Tamaki N, Matsumoto S. The effects of ticlopidine and nicardipine on the prevention of symptomatic vasospasm after aneurismal rupture. No Shinkei Geka (Jap). 1988;16:741–746
  15. Haley EC, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurismal subarachnoid haemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78:537–547
  16. Haley EC, Kassell NF, Torner JC. A randomized trial of nicardipine in subarachnoid haemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78:548–553
  17. Haley EC, Kassell NF, Torner JC, Truskowski LL, Germanson TP. A randomized trial of two doses of nicardipine in aneurismal subarachnoid haemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1994;80:788–796
  18. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists for aneurismal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2000;(2):CD000277
  19. Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004;25:819–826
  20. Avitsian R, Fiorella D, Soliman MM, Mascha E. Anesthetic considerations of selective intra-arterial nicardipine injection for intracranial vasospasm: a case series. J Neurosurg Anesthesiol. 2007;19:125–129
  21. Tejada JG, Taylor RA, Ugurel MS, Hayakawa M, Lee SK, Chaloupka JC. Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid haemorrhage-associated vasospasm: initial clinical experience with high-dose infusions. AJNR Am J Neuroradiol. 2007;28:844–848
  22. Kasuya H, Onda H, Takeshita M, Okada Y, Hori T. Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans. Stroke. 2002;33:1011–1015
  23. Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid haemorrhage. Neurosurgery. 2005;56:895–902
  24. Barth M, Capelle HH, Weidauer S, Weiss C, Munch E, Thome C, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurismal subarachnoid haemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke. 2007;38:330–336
  25. Krischek B, Kasuya H, Onda H, Hori T. Nicardipine prolonged-release implants for preventing cerebral vasospasm after subarachnoid haemorrhage: effect and outcome in the first 100 patients. Neurol Med Chir (Tokyo). 2007;47:389–394
  26. Medical Reseach Council Working Party . Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Br Med J. 1988;296:1565–1570
  27. Barry DI, Vorstrup S, Jarden JO, Svendsen UG, Braendstrup O, Graham DI, et al. Effects of antihypertensive drugs on the cerebral circulation. Acta Med Scand. 1993;677:143–147
  28. Inzitari D, Poggesi A. Calcium channel blockers and stroke. Aging Clin Exp Res. 2005;17:16–30
  29. Martì Masso JF, Lozano R. Nicardipine in the prevention of cerebral infarction. Clin Ther. 1990;12:344–351
  30. Lozano R, Balaguer A. Nicardipine in the treatment of outpatients with cerebrovascular disorders. Clin Ther. 1991;13:496–499
  31. Ribas Mundò M, Lozano R. The influence of nicardipine in patients with high risk of stroke. J Cardiovasc Pharmacol. 1990;16:S16–S19
  32. Yao LP, Ding DY. Effect of nicardipine on somatosensory evoked potentials in patients with acute cerebral infarction. J Neurol Neurosurg Psychiatry. 1990;53:844–846
  33. Rosenbaum DM, Zabramski J, Frey J, Yatsu F, Marler L, Spetzler R, et al. Early treatment of ischemic stroke with a calcium antagonist. Stroke. 1991;22:437–441
  34. Lisk DR, Grotta GC, Lamki LM, Tran HD, Taylor JW, Molony DA, et al. Should hypertension be treated after acute stroke?. Arch Neurol. 1993;50:855–862
  35. Uematsu D, Watanabe S, Katayama T. Nicardipine improves cerebral hemodynamics in acute and subacute stroke. Neurology. 1992;42(Suppl 3):395
  36. Gamèz NM, Soto Mas JA, Aguilar Martinez JL, Bermùdez Garcia JM, Salim A, Ramos Jimènez A, et al. Ensayo clìnico controlado a doble ciego: nicardipina frente a placebo en la isquemia cerebral focal aguda. Med Clin (Barc). 1988;90:690–692
  37. Shah QA, Georgiadis A, Suri MF, Rodriguez G, Qureshi AI. Preliminary experience with intra-arterial nicardipine in patients with acute ischemic stroke. Neurocrit Care. 2007;7:53–57
  38. Liu-Deryke X, Janisse J, Coplin WM, Parker D, Norris G, Rhoney DH. A Comparison of nicardipine and labetalol for acute hypertension management following stroke. Neurocrit Care. 2008;9:167–176
  39. Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ. 1996;312:805–808
  40. Glynn RJ, Beckett LA, Hebert LE, et al. Current and remote blood pressure and cognitive decline. JAMA. 1999;281:438–445
  41. Eftekhari H, Uretsky S, Messerli FH. Blood pressure, cognitive dysfunction and dementia. J Am Soc Hypertens. 2007;1:135–144
  42. Staessen JA, Richart T, Birkenhäger WH. Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension. 2007;49:389–400
  43. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J Neurol Sci. 2002;203–204:147–151
  44. Handa J, Matsuda M, Nakasu Y, Nakasu S, Kidooka M, Watanbe K. Clinical effect of a new 1,4-dihydropyridine derivative, YC-93, in patients with cerebrovascular diseases. Arch Jpn Chir. 1979;48:400–403
  45. Miyamoto T. Effect of long-term treatment with YC-93 (nicardipine HCl), a 1,4,-dihydropyridine derivative, on obstructive cerebrovascular disorders. Clin Rep (Jap). 1981;15:426–434
  46. Saku J. Clinical use of YC-93 (nicardipine HCl) in patients with cerebrovascular disorders. Part 2. Long-term use of YC-93. Clin Rep (Jap). 1981;15:233–242
  47. Tajika Y. Clinical study of nicardipine hydrochloride (Perdipine) in patients with cerebral vascular disorders. Basic Clin Med (Jap). 1982;16:315–318
  48. Tamura M. Clinical efficacy of nicardipine hydrochloride for the treatment of various cerebrovascular disorders. Clin Rep (Jap). 1982;16:257–262
  49. Hiramine T. Clinical effects of nicardipine hydrochloride (perdipine) on cerebrovascular disorders. Med Consult New Remed (Jap). 1983;20:97–102
  50. Kuriyama Y, Sawada T, Niimi T, Naritomi H, Kinugawa H, Fukushima M, et al. Effects of nicardipine and nifedipine on cerebral circulation in cerebrovascular disorders. J Cereb Blood Flow Met. 1983;3(Suppl 1):560–561
  51. Iijima K. Effects of perdipine on post apoplectic disorders and cerebral arteriosclerosis. Clin Rep (Jap). 1983;17:153–162
  52. Ikeda T. Clinical trial of YC-93 (nicardipine HCl) in patients with cerebral vascular disorders and cerebral blood flow disturbances. Clin Rep (Jap). 1983;17:263–277
  53. Iwabuchi S. Effects and safety of nicardipine hydrochloride in patients with higher cerebral dysfunction. Med Consult New Remed (Jap). 1987;24:169
  54. De Cabo JP. Estudio clìnico de un derivado piridìnico nitrofenilado, la nicardipina, como agente vasodilatator cerebral. Rev Esp Geriatr Gerontol. 1984;19:311–315
  55. Vintrò Molins C, Viaplana Màs JM. Ensayo clìnico a doble ciego parallelo de nicardipina frente a placebo en pacientes con insuficiencia vascular cerebral crònica. Med Clin (Barc). 1985;84:308–311
  56. Gonzàles-Elipe J, Romero J, Lozano R. Nicardipine in the treatment of the cerebral ischemic attack sequelae. Double-blind study versus placebo. In: International Symposium on Calcium Antagonists (New York). 1987;
  57. Spanish Group of Nicardipine Study in Vascular Dementia . An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia. Rev Neurol. 1999;15(28):835–845
  58. Gonzalez-Gonzalez JA, Lozano RA. Study of the tolerability and effectiveness of nicardipine retard in cognitive deterioration of vascular origin. Rev Neurol. 2000;30:719–728
  59. De Fabritiis A, Pili C, Scondotto G, Borgatti E. Modificazioni delle resistenze vascolari cerebrali valutate mediante tecnica del doppler carotideo: effetti della nicardipina verso cinnarizina. Giorn It Angiol. 1985;5:41–59
  60. Puccinelli F, Pieraccini F, Tomei GP, Gargiulo L. L' ipertensione arteriosa nella fase riabilitativa dell' ictus cerebrale. Clin Ther. 1989;130:29–35
  61. Scarzella L, Bergamasco B. La nicardipina nella terapia dell' ipertensione arteriosa dell' anziano affetto da sindrome psico-organica. Clin Ther. 1989;130:171–178
  62. Weir B. Calcium antagonist, cerebral ischemia and vasospasm. Can J Neurol Sci. 1984;11:239–246
  63. Denolle T, Sassano P, Allainc H, Bentue'-Ferrerc D, Bretona S, Cimarostic I, et al. Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients. Fundam. Clin. Pharmacol. 2002;16:527–535
  64. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;CD000147
  65. Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke. 2005;36:619–624
  66. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007;117:3393–3402

PII: S0022-510X(09)00440-7

doi: 10.1016/j.jns.2009.02.335

Journal of the Neurological Sciences
Volume 283, Issue 1 , Pages 219-223 , 15 August 2009

Article Tools